Methods for the administration of iloperidone
AssigneeVanda Pharmaceutials Inc.
InventorsCurt Wolfgang, Mihael Polymeropoulos, Christian Lavedan, Simona Volpi
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
Claims20
A method for treating a patient with a compound that is iloperidone or a metabolite thereof, wherein the patient is suffering from schizophrenia, the method comprising the steps of:
- determining that the patient demonstrates reduced CYP2D6-mediated metabolism relative to wild type by:
- obtaining or having obtained a biological sample from the patient;
- performing or having performed a genotyping assay on the biological sample;
- and
- determining that the patient has a genotype associated with reduced CYP2D6-mediated metabolism, wherein the genotype includes two CYP2D6*41 alleles;
- and
- administering the compound to the patient in a first amount that is one of 25%, 50%, or 75% of a second amount of 24 mg/day, that would be administered to a patient demonstrating CYP2D6-mediated metabolism consistent with a wild type CYP2D6 genotype, and
- wherein a risk of QTc prolongation for the patient is lower following the administration of the first amount of the compound than it would be if the compound were administered in the second amount.
A method of treating a patient who is suffering from a schizoaffective disorder, depression, Tourette's syndrome, a psychotic disorder or a delusional disorder, the method comprising:
- determining that the patient has a genotype associated with reduced CYP2D6-mediated metabolism by:
- obtaining or having obtained a biological sample from the patient, and
- performing or having performed a genotyping assay on the biological sample to determine that the patient has a genotype associated with reduced CYP2D6-mediated metabolism, wherein the genotype includes two CYP2D6 *41 alleles;
- and
- administering a compound that is iloperidone or a metabolite thereof to the patient in a first amount,
- wherein the first amount of the compound is 25%, 50%, or 75% of a second amount of 24 mg/day of the compound that would be administered to a patient demonstrating CYP2D6-mediated metabolism consistent with a wild type CYP2D6 genotype,
- wherein a risk of QTc prolongation for the patient is lower following the administration of the first amount of the compound than it would be if the compound were administered in the second amount.
A method of treating a patient who is suffering from a schizoaffective disorder, depression, Tourette's syndrome, a psychotic disorder or a delusional disorder, the method comprising:
- determining that the patient is at risk for iloperidone-induced QTc prolongation by:
- obtaining or having obtained a biological sample from the patient, and
- performing or having performed a genotyping assay on the biological sample to determine whether the patient has a CYP2D6 poor metabolizer genotype that includes two CYP2D6 *41 alleles, wherein the presence of the CYP2D6 poor metabolizer genotype indicates risk for iloperidone-induced QTc prolongation, and
- administering a compound that is or a metabolite thereof, to the patient in a first amount,
- wherein the first amount of the compound is one of 25%, 50%, or 75% of a second amount of 24 mg/day of the compound, wherein the second amount causes an iloperidone blood exposure level that is therapeutically effective in a patient not having a CYP2D6 poor metabolizer genotype.
Dependencies are inferred from the claim text.